Tag Archives: Excipients

IMCD to acquire Indian Pharma Excipients Distributor Signet

Further Pharma Growth for IMCD in Asia-Pacific and Middle East, Africa

Specialty chemicals and food ingredients distributor IMCD N.V. (Rotterdam, The Netherlands) announced yesterday that it will acquire 100% of Signet Excipients Private Limited [“Signet”] (Mumbai, Maharashtra – India), one of the leading distributors of excipients in India, in a two-phase transaction. IMCD will now acquire 70% of the share capital from the founders, and the remaining 30% by 2024. Harish Shah, Founder and Managing Director oft Signet, will continue to lead the company post completion of the first phase.

Since its foundation in 1986, Signet grew from a small distribution company to one of the leading distributors of excipients in India, the anouncement said. The company focusses on the distribution of Pharmaceutical, Nutraceutical and Bio-pharma Excipients across a range of categories such as Diluents, Fillers, Sweeteners, Disintegrants, Binders, Surfactants and others. Besides sales in India, Signet is also active in Bangladesh, the Middle East and Africa,  currently serving more than 900 customers, with more than 400 products from leading excipient producers. With approximately 100 employees, Signet generated revenue of ca. EUR 152 mn (INR 13.2 bn) in the last twelve months (up to and including June 2020), and realised a normalised EBITA of ca. EUR 39 million (INR 3.4 bn).

IMCD said it considers Signet to be well aligned with the IMCD business model and strategy, providing a significant platform for further growth in India and the Asia-Pacific region, giving the transaction a strong strategic rationale.

Closing of the transaction is subject to customary closing conditions and regulatory approval. It is expected to take place in Q4-2020. No financial details were disclosed on this transaction.

Source: IMCD press release

DistriConsult comment: In a separate anouncement today IMCD said, to finance the purchase of the first tranche of 70% of the shares of Signet, it has successfully raised ca. EUR 400 mn through an accelerated bookbuild offering of new shares. Any surplus will be used for “general corporate purposes”.

HGE – DCG / 16.09.2020

Azelis to acquire Excipients Business from Indian Distributor S. Zhaveri Pharmakem Pvt. Ltd.

Azelis with another Acquisition to enhance Industry Coverage in India

Specialty chemicals and food ingredients distributor Azelis S.A. (Munsbach, Luxembourg) has announced that it has signed an agreement to acquire 100% of the distribution and indent business of S. Zhaveri Pharmakem Pvt. Ltd. (Mumbai, India), a distributor of Pharma Excipients for an undisclosed amount.

 

S. Zhaveri is was founded in 1951 and has to-date been owned 100% by the Javeri family. The company serves more than 250 customers with products from international as well as domestic principals. All its employees in the distribution business will become part of Azelis. Following the closing, Mrs. Uma Javeri and Ms. Sonali Sheth will support the integration of S. Zhaveri Pharmakem’s distribution business into Azelis, and will lead the entire pharma business of Azelis in India.

 

No financial information was disclosed on the transaction.

 

Source: Azelis press release

 

HGE – DCG / 03.02.2020

IMCD has acquired Colombian Pharma Distributor Unired Químicas

Third Acquisition this Month for IMCD further enhancing Presence in the Pharma Sector

Specialty chemicals and food ingredients distributor IMCD N.V. (Rotterdam, The Netherlands)  announced that it has acquired 100% of the outstanding shares of specialty chemicals and ingredients distributor Unired Químicas SAS  (Bogota, Colombia). 

 

Unired serves customers in the Pharmaceutical, Food and Personal Care markets. Founded in 1991, the company generated revenues of USD 8 mn with 15 employees in 2018.

 

No financial details were disclosed on the transaction. The acquired company will be fully integrated into IMCD’s organisation during 2020.

 

Source: IMCD press release, Unired website

 

HGE – DCG / 22.11.2019

IMCD to acquire significant Share in Korean Distributor Whawon Pharm Co. Ltd.

Second Acquisition within one Week helps to further enhance IMCD’s Coverage of Pharma Sector

Specialty chemicals and food ingredients distributor IMCD N.V. (Rotterdam, The Netherlands)  announced that it has signed an agreement to acquire 57% of the outstanding shares of pharmaceutical ingredients distributor Whawon Pharm Co. Ltd. [“Whawon”] (Seoul, South Korea). According to IMCD’s announcement, Whawon is a leading distributor in South Korea with a focus on Pharmaceutical Formulation Ingredients. Founded in 1998, the company generated revenues of KRW 57 bn (approx. EUR 44 mn) with 54 employees in 2018.

Initially, IMCD will acquire 57% of the total share capital from the existing Whawon management, who will continue to lead the company. The remaining 43% will be held by management for a period up to five years after closing.

No financial details were disclosed on the transaction, which is subject to fulfillment of certain closing conditions.

Source: IMCD press release

HGE – DCG / 05.11.2019

IMCD to acquire DCS Pharma AG in Switzerland

Existing IMCD Excipients Offering to be augmented with strong API Presence of newly acquired Entity

Specialty chemicals and food ingredients distributor IMCD N.V. (Rotterdam, The Netherlands)  announced that it has signed an agreement to acquire 100% of the outstanding shares of DCS Pharma AG (Basel, BS – Switzerland) in a two-step process for an undisclosed sum. 90% of the shares will be acquired at the closing of the transaction, the remaining 10% ca. two years later, effective 31. December 2021.

DCS Pharma, a distributor of Active Pharmaceutical Ingredients (“APIs”), traces its roots back to two Swiss distributors of products  for the pharma and the nutraceutical industry, the Pharma business of Dolder AG and ChemSwiss AG, which were merged in 2016. Today the company operates with a total of 64 employees in seven countries besides Switzerland, including Spain, Italy, Germany, Mexico and China. In 2018, it generated sales of CHF 68 mn, IMCD said in a statement.

IMCD further said it expects formulation and marketing synergies between the newly acquired API activities and its existing business, which is mainly focused on Excipients. Customers of DCS Pharma should benefit from a significantly increased network, according to its CEO Beat Berger.

No financial details were disclosed on the transaction, which is subject to fulfilling customary closing conditions.

Source: IMCD press release

HGE – DCG / 01.11.2019